Core Insights - The company is actively expanding its overseas market presence, with product exports projected to increase from 28.54% in 2024 to 38.6% by mid-2025 [2] - A joint venture with Huahai Pharmaceutical is focused on high-end steroid raw material production, with two production workshops already in trial production [3] - The company is leveraging synthetic biology technology to optimize processes and enhance customer collaboration in response to global pharmaceutical supply chain restructuring [5] Overseas Market Expansion and Future Plans - The company's export ratio is on the rise, with a target of 28.54% for 2024 and an increase to 38.6% by mid-2025 [2] - The company aims to strengthen brand promotion and sales channels through overseas subsidiaries and local partnerships [2] Raw Material Layout and Progress - The joint venture, Huahai Gongtong, aims to integrate strengths for high-end steroid raw material production, with plans divided into two phases covering 13 products [3] - Two production workshops are in trial production, with another set to begin soon, and preparations for registration documentation are underway [3] Applications of Steroid Products - Steroid drugs are categorized into sex hormones, progestogens, corticosteroids, and others, with applications in hormone replacement, disease treatment, and inflammation management [4] - The range of products and applications is continuously expanding [4] Response to Supply Chain Restructuring and Core Competitiveness - The global restructuring of the pharmaceutical supply chain is influencing the company's capacity layout and customer collaboration models [5] - The company views full supply chain collaboration as a core competitive advantage, enhancing efficiency across starting materials, intermediates, and raw materials [5] Plans for High-Value-Added Fields - Over the next 2-3 years, the company plans to extend into high-value-added areas, leveraging its complete industrial chain and professional R&D platform [6] - The focus will be on high-end intermediates and customized products [6]

证券代码：300966 证券简称：共同药业 为计生用药。 皮质激素主要用于物理性损伤、化学性损伤、免疫性损伤以及无菌性炎症 等各种急慢性炎症的治疗，另外还用于抗休克、退热、刺激骨髓造血功能、维 持人体内水和电解质的平衡等，比如治疗过敏性皮炎用药氟轻松、消炎药地塞 米松、抗哮喘用药氟替卡松、布地奈德等。 甾体药物其他类包含胆酸类用药熊去氧胆酸，心血管用药依普利酮，抗癌 药物阿比特龙，肌松药物维库溴铵、罗库溴铵，利尿剂螺内酯等不同类别用药， 甾体其他类药物品种种类不断增加，应用范围不断扩大，在甾体类药物中极具 潜力。 5、最近几年全球医药产业链都在经历重构，作为国内甾体药物原料的核 心供应商，如何看待这些趋势对自身业务的影响？是否有针对性的策略调整？ 答：全球医药产业链重构对我们作为甾体药物原料供应商的影响主要体现 在产能布局和客户合作模式方面。随着抗生素使用的节制，甾体药物在抗炎、 免疫、生殖健康等领域的应用有望进一步扩大。与此同时，全球大健康产业和 老龄化趋势也为我们带来了新的发展机遇，特别是在生殖健康、老年慢性病管 理等领域。为应对上述趋势，我们在产能方面，积极应用合成生物学等技术优 化工艺，提升生产效率和 ...

证券之星价投圈财报分析工具显示：业务评价：去年的净利率为-5.9%，算上全部成本后，公司产品或 服务的附加值不高。从历史年报数据统计来看，公司上市以来中位数ROIC为9.45%，投资回报也较好， 其中最惨年份2024年的ROIC为-0.46%，投资回报极差。公司历史上的财报相对一般(注：公司上市时间 不满10年，上市时间越长财务均分参考意义越大。)，公司上市来已有年报3份，亏损年份1次，需要仔 细研究下有无特殊原因。商业模式：公司业绩主要依靠资本开支驱动，还需重点关注公司资本开支项目 是否划算以及资本支出是否刚性面临资金压力。需要仔细研究这类驱动力背后的实际情况。 财报体检工具显示：建议关注公司现金流状况(货币资金/总资产仅为4.56%、货币资金/流动负债仅为 35.76%、近3年经营性现金流均值/流动负债仅为2.09%)建议关注公司债务状况(有息资产负债率已达 41.79%、有息负债总额/近3年经营性现金流均值已达156.56%)建议关注财务费用状况(财务费用/近3年经 营性现金流均值已达287.78%)建议关注公司应收账款状况(年报归母净利润为负) 据证券之星公开数据整理，近期共同药业(300966)发布 ...

Group 1 - Xianju Pharmaceutical Co., Ltd. has experienced a decline in stock price for seven consecutive trading days, with a cumulative drop of -5.94% [1] - The company, founded in 1972, aims to become one of the top ten steroid drug suppliers globally and focuses on the steroid hormone sector [1] - In the second quarter of this year, Xianju Pharmaceutical was added to the top ten shareholders of the Xinchuan He Feng three-year holding mixed fund, which has achieved a year-to-date return of 20.55% [1] Group 2 - Yang Shijin and Zhu Kefei are the current fund managers of the Xinchuan He Feng three-year holding mixed fund [4] - Zhu Kefei has been managing the fund since July 2, 2025, and has a tenure of 36 days with a return of 8.40% [3] - Xingsheng Global Fund Management Co., Ltd. was established in September 2003 and is co-owned by Xinyi Securities Co., Ltd. and Global Life Insurance International Company [3]